BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35643842)

  • 1. Healthcare costs and resource utilization associated with renal cell carcinoma among older Americans: A longitudinal case-control study using the SEER-Medicare data.
    Bhandari NR; Kale HP; Carroll NV; McAdam-Marx C; Ounpraseuth ST; Tilford JM; Kamel MH; Kent EE; Payakachat N
    Urol Oncol; 2022 Jul; 40(7):347.e17-347.e27. PubMed ID: 35643842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of renal cell carcinoma among older adults in the targeted therapy era.
    Kale HP; Mays DP; Nadpara PA; Slattum PW; Paul AK; Carroll NV
    Urol Oncol; 2019 Jun; 37(6):356.e19-356.e28. PubMed ID: 30846388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
    Hollenbeak CS; Nikkel LE; Schaefer EW; Alemao E; Ghahramani N; Raman JD
    J Manag Care Pharm; 2011 Oct; 17(8):610-20. PubMed ID: 21942302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
    Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
    [No Abstract]   [Full Text] [Related]  

  • 5. Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States.
    Jonasch E; Song Y; Freimark J; Berman R; Nguyen H; Signorovitch J; Sundaram M
    Clin Genitourin Cancer; 2023 Apr; 21(2):238-247. PubMed ID: 36682891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
    Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
    Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
    Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
    J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare costs and utilization associated with pain among breast cancer survivors: a propensity score matched cohort study using SEER-Medicare data.
    Lakkad M; Martin B; Li C; Harrington S; Dayer L; Painter JT
    J Cancer Surviv; 2023 Aug; 17(4):917-950. PubMed ID: 36369622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of renal cell carcinoma in the US: Part II--an updated analysis.
    Shih YC; Chien CR; Xu Y; Pan IW; Smith GL; Buchholz TA
    Pharmacoeconomics; 2011 Apr; 29(4):331-41. PubMed ID: 21395352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
    Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
    BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to and persistence with adjuvant hormone therapy, healthcare utilization, and healthcare costs among older women with breast cancer: A population-based longitudinal cohort study.
    Zheng D; Thomas J
    J Geriatr Oncol; 2023 Nov; 14(8):101599. PubMed ID: 37598659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare resource use and costs associated with chronic kidney disease in US private insurance patients with multiple myeloma.
    Bhowmik D; Song X; Intorcia M; Kent ST; Shi N
    J Oncol Pharm Pract; 2019 Jun; 25(4):855-864. PubMed ID: 29661050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
    Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
    J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.
    Pike C; Birnbaum HG; Schiller M; Sharma H; Burge R; Edgell ET
    Pharmacoeconomics; 2010; 28(5):395-409. PubMed ID: 20402541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic impact of epilepsy and the cost of nonadherence to antiepileptic drugs in older Medicare beneficiaries.
    Ip Q; Malone DC; Chong J; Harris RB; Labiner DM
    Epilepsy Behav; 2018 Mar; 80():208-214. PubMed ID: 29414554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.
    Amand C; Tong S; Kieffer A; Kyaw MH
    BMC Health Serv Res; 2018 Apr; 18(1):294. PubMed ID: 29678177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.